创新药，大消息！刚刚，重磅发布

Core Points - The 2025 National Medical Insurance Drug List has been officially released, adding 114 new drugs, with 19 drugs included in the first Commercial Health Insurance Innovative Drug List [1][4] - This marks the eighth consecutive year of adjustments to the National Medical Insurance Drug List [1] Group 1: National Medical Insurance Drug List - The new drug list will take effect from January 1, 2026, replacing the 2024 version [3] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [5] - The inclusion of 50 innovative drugs in this adjustment reflects an overall success rate of 88%, up from 76% in 2024 [5] - The updated list enhances coverage for critical areas such as cancer, chronic diseases, rare diseases, and pediatric medications [5] - Local authorities are required to strictly implement the new drug list and update their information systems accordingly [5] Group 2: Commercial Health Insurance Innovative Drug List - The first Commercial Health Insurance Innovative Drug List is a significant breakthrough in the 2025 drug list adjustments [7] - The 19 drugs included in this list cover treatments for various conditions, including CAR-T therapies for cancer and treatments for rare diseases like neuroblastoma and Gaucher disease [8] - The National Medical Insurance Bureau emphasizes the need to promote the use of drugs listed in the Commercial Health Insurance Innovative Drug List and integrate them into commercial health insurance coverage [8]